Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 30, 2025 08:00 ET | Source: Marker Therapeutics

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
July 30, 2025 07:30 ET | Source: Sensei Biotherapeutics

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
July 30, 2025 07:05 ET | Source: Anika Therapeutics Inc.

Anika Reports Second Quarter 2025 Financial Results

Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more...
July 30, 2025 07:00 ET | Source: Anika Therapeutics Inc.

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function ...
July 30, 2025 04:10 ET | Source: Dr. Falk Pharma

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR...
July 29, 2025 23:50 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
July 29, 2025 16:01 ET | Source: Larimar Therapeutics

Larimar Therapeutics Announces Proposed Underwritten Public Offering

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
July 28, 2025 07:00 ET | Source: CervoMed Inc.

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at...
July 24, 2025 14:00 ET | Source: Merakris Therapeutics

Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit

RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit...